GlassScriptPhysician profile
Hardik D Patel
NPI 1568806214
$3,704.95
in general payments reported to CMS, 2019-2025
19 companies · $1,090 in 2025
The $1,090 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.18 · 2020: $237 · 2021: $303 · 2022: $284 · 2023: $1,036 · 2024: $694 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,819.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $826.74 | 2020-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $498.79 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $450.53 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Genzyme Corporation | $328.41 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $251.28 | 2020-2023 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $210.28 | 2025 | Neffy |
| Optinose US, INC. | $204.06 | 2020-2025 | |
| Grifols USA, LLC | $184.38 | 2020-2025 | Xembify |
| Getinge USA Sales, LLC | $132.82 | 2023 | Vasoview Hemopro 2, Icast |
| Kaleo, INC. | $131.60 | 2022-2024 | Auvi-Q |
| Abbvie INC. | $99.05 | 2024 | |
| Novartis Pharmaceuticals Corporation | $83.43 | 2019-2025 | |
| Octapharma USA, INC. | $79.10 | 2023 | Cutaquig |
| Blueprint Medicines Corporation | $62.49 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $51.96 | 2023-2025 | Xolair |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $43.69 | 2025 | |
| Olympus America INC. | $27.47 | 2024 | |
| Azurity Pharmaceuticals, INC. | $21.50 | 2025 | Alvesco |
| Phadia US INC. | $17.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hardik Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.